Highest-materiality recent filing
Meng Li notified Change Agents Corporation on Oct 7, 2026 she is resigning as Interim CEO, Chief Operating Officer and Secretary, effective Oct 8, 2026.
Change Agents (CHGA) issues $336,000 in OID notes and 100,000-share pre-funded warrants
On Sept. 30, 2026, Change Agents issued Second Tranche September 2026 OID Notes: $336,000 principal, $36,000 OID, $300,000 gross proceeds.
Change Agents issues $280K OID notes, amends Hudson equity line, grants warrants
Issued $280K aggregate OID notes (gross $250K; $30K discount) at 7% interest, maturing 4/8/2027; prepayable at 105%.
Change Agents issues $280K OID notes, amends Hudson equity line, issues pre-funded warrants
Issued $280,000 OID notes (gross $250k); proceeds repay $19,710 Vanquish note and $19,710 June 2025 notes.
Change Agents (CHGA) implements 1-for-20 reverse split to meet Nasdaq $1 bid requirement
Reverse split effective 4:01 p.m. ET Aug 28, 2026; split-adjusted trading starts Aug 31 on Nasdaq under CHGA.
Change Agents completes Phase 2 of Catch-Up AI video platform; AWS $125K grant received
Phase 2 development of Catch-Up agentic AI video studio completed on Aug 31, 2026, with AWS providing $125,000 in funding.
Change Agents amends equity purchase agreement with Hudson Global, cuts price to $0.20/share
First Amendment dated Aug 21, 2026 to July 22, 2026 Equity Purchase Agreement with Hudson Global Ventures.
Change Agents raises $550K via OID notes, issues 1M pre-funded warrants
Issued $616,000 principal OID notes (incl. $66,000 OID) for $550,000 gross proceeds to accredited investors.
Change Agents issues 1.55M shares for consulting services under unregistered sale
Issued 1,550,000 shares of common stock to consultants from July 30 to Aug 1, 2026.
Change Agents Corp. enters $825K loan, issues 360K shares to lender
Principal $825,000; net proceeds $254,350 after $41,250 admin fee and $529,400 prior loan repayment.
Change Agents Corp enters $10M equity purchase agreement with Hudson Global Ventures
Entered Equity Purchase Agreement with Hudson Global Ventures for up to $10,000,000 of common stock.
Name change to Change Agents Corporation effective July 20, 2026; no stockholder vote required.
Issued 400 shares of Series F Convertible Preferred Stock at $1,000 stated value each to investor Allen O. Cage Jr. for $400,000.
Reverse stock split (1:2 to 1:25) approved: 3,605,584 for, 741,154 against; board may implement before June 9, 2027.
Avalon GloboCare issues $500K in notes (18.75% OID); appoints Sam Knipper CFO, Luisa Ingargiola CSO
Issued $250K note to Dune Equity Holdings ($200K gross) and $250K note to FirstFire Global Opportunities ($200K gross), each with $50K original issue discount.
Avalon GloboCare files pro forma financials for sale of real estate unit to Chairman for $9M
Sale of Avalon RT 9 Properties to Chairman Wenzhao Lu for $9M; excess proceeds ~$2M recorded to additional paid-in capital.
Avalon Quantum AI collaborates with AWS and Caylent for Catch-Up Phase 2 development
Avalon subsidiary Avalon Quantum AI LLC collaborates with AWS to support Phase 2 of Catch-Up agentic AI video platform.
Avalon GloboCare receives Nasdaq notice of non-compliance with minimum bid price rule
Nasdaq notified Avalon GloboCare on April 15, 2026 of bid price deficiency per Listing Rule 5550(a)(2).
Avalon Globocare sets 2026 Annual Meeting for June 9; shareholder proposal deadline April 12
2026 Annual Meeting scheduled for June 9, 2026, held virtually; record date is May 15, 2026.
Avalon GloboCare shareholders approve reverse split authorization but no split planned
On March 30, 2026, shareholders approved a future reverse stock split authorization; Board not planning to implement now.
Avalon Globocare shareholders approve reverse stock split, note conversions, and Lu exchange
All 7 proposals passed at special meeting on March 30, 2026.
Avalon GloboCare corrects share count in $2.8M private placement
The amendment corrects the number of shares reported under Item 3.02 in the original March 2 filing.
Avalon Globocare awards $175K bonus to CFO, increases lead director fees to $95K/yr
CFO Luisa Ingargiola awarded $175,000 bonus for efforts during 2025 fiscal year.
Avalon GloboCare closes $3.25M private placement with up to $6.5M additional warrant proceeds
Issued 6,372,550 shares (or pre-funded warrants) at $0.51, plus Series A-1/A-2 warrants for 6,372,550 shares each at $0.51.
Avalon GloboCare subsidiary accepted into AMD AI Developer Program
Avalon Quantum AI LLC accepted into AMD AI Developer Program, gaining access to AMD Developer Cloud credits and compute resources.
Avalon Globocare issues $233,910 convertible note; three directors resign, three appointed
Note principal $233,910 (incl. $26,910 OID); net proceeds $207,000; matures Feb 15, 2027.
Avalon GloboCare sells 100% of property subsidiary to Chairman for $9M, relieved of $5.9M mortgage
Sold 100% membership interests in Avalon RT 9 Properties, LLC to Chairman Wenzhao Lu for $9M total consideration.
Avalon GloboCare subsidiary files provisional patent for audience-adaptive AI video platform
U.S. Provisional Patent Application No. 63/961,892 filed for system that generates multiple personalized commentary video variants while preserving factual integrity.
Avalon GloboCare issues $233,910 promissory note to Vanquish Funding Group at 13% OID
Principal $233,910; purchase price $207,000 (13% original issue discount); 12% one-time interest.
Avalon GloboCare converts $2.6M of debentures to common stock, slashes debt
Converted $2.6M principal from June 2024 institutional note into shares; $288K repaid in cash.
Avalon GloboCare terminates merger with YOOV Group; subsidiary files AI patent
Mutually terminated March 2025 merger agreement with YOOV Group Holding Limited, effective Jan 21, 2026.
Avalon GloboCare renews FDA registration for KetoAir; plans Q2 2026 launch via Catch-Up AI platform
FDA registration renewed for KetoAir breathalyzer (Reg. No. 3026284320) for ketogenic health management.
Avalon GloboCare regains Nasdaq minimum equity compliance, launches generative AI video platform
Nasdaq confirmed compliance with minimum stockholders' equity rule 5550(b); previous hearing cancelled.
Avalon GloboCare holds annual meeting; all director nominees elected, auditor ratified
Stockholders elected all six director nominees: Wenzhao Lu, Lourdes Felix, Steven Sanders, William Stilley III, Wilbert Tauzin II, Tevi Troy.
Avalon GloboCare touts RPM's Catch-Up generative AI video platform for KetoAir marketing
Board director Michael Mathews, also RPM CEO, discussed Catch-Up SaaS platform on ProactiveInvestors.
Acquired RPM Interactive, a generative AI SaaS platform for automated short-form video, via merger with subsidiary Avalon Quantum AI.
Avalon GloboCare reports Q3 2025 KetoAir progress: UK launch and first-responder program
Launched four-month Holistic Health Reset program for 50 first responders in Nevada using KetoAir for daily metabolic monitoring.
Avalon GloboCare receives Nasdaq delisting notice over equity deficiency
On Nov 19, 2025, Nasdaq notified Avalon GloboCare (ALBT) it is not in compliance with Listing Rule 5550(b) due to stockholders' equity of ($3,891,270) vs required $2.5M.
Avalon GloboCare reveals YOOV preliminary FY2025 revenue of $59.3M, net income $3.8M
YOOV's preliminary unaudited FY2025 (year ended March 31, 2025): revenue $59.3M, net income $3.8M (206% growth).
Avalon GloboCare raises $500K via stock sale, amends Series C preferred, and updates note balance
Issued 141,643 shares at $3.53/share to York Sun Investment for $500,000.
Avalon GloboCare to launch KetoAir breathalyzer sales in UK starting September 1, 2025
KetoAir breathalyzer sales in UK begin September 1, 2025 at www.KetoAir.uk; device measures breath acetone for ketosis tracking.
Avalon GloboCare issues 221,000 unregistered shares upon note conversion; total shares 3.69M
Issued 221,000 shares of unregistered common stock between July 30 and August 6, 2025 to a noteholder upon partial conversions of a promissory note.
Avalon GloboCare issues 393,716 unregistered shares in July 2025 for note conversions and services
211,400 shares issued July 16-17 on partial conversion of promissory note; outstanding then 3,286,793.
Avalon GloboCare extends maturity of senior secured promissory note to August 31, 2025
Waiver with Mast Hill Fund extends maturity of promissory note from June 5, 2025 to August 31, 2025.
Avalon GloboCare subsidiary signs distribution agreement with Saga Health for KetoAir breathalyzer
Q&A Distribution, LLC entered a wholesale distribution agreement with Saga Health Corporation for the KetoAir breathalyzer.
Avalon GloboCare raises $300,000 via Series C Convertible Preferred Stock private placement
Sold 300 shares of Series C Convertible Preferred Stock to Mast Hill Fund for $300,000; net proceeds $290,000 after legal fees.
Sold 121,200 shares and pre-funded warrants for 354,300 shares at $475,500; net proceeds $450,500.
Avalon GloboCare granted Hong Kong patent for CAR-T/CAR-NK cell technology
Hong Kong Intellectual Property Department issued standard patent HK40074322 for CAR-T and CAR-NK cell technology.
Avalon GloboCare issues $200K convertible notes to two accredited investors
Two convertible promissory notes of $100K each issued to Anthony Macaluso and Lawrence Bruno on July 3, 2025.
Definitive agreement for co-development of VOC nanosensor-based point-of-care cannabis breathalyzer.
On October 7, 2026, Meng Li notified Change Agents Corporation (the “Company”) of her decision to resign from her position as the Company’s Interim Chief Executive Officer, Chief Operating Officer and Secretary, effective October 8, 2026.
On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).
On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).
Max materiality 0.90 · Median 0.53 · Most common event other_material